|
|
Apoptotic Susceptibility of Cancer Cells Selected for Camptothecin Resistance:
Gene Expression Profiling, Functional Analysis, and Molecular Interaction Mapping
William C. Reinhold, Hosein Kouros-Mehr, Kurt W. Kohn, Alika K. Maunakea, Samir Lababidi,
Anna Roschke, Kristen Stover, Jes Alexander, Panayotis Pantazis, Lance Miller,
Edison Liu, Ilan R. Kirsch, Yoshimasa Urasaki, Yves Pommier, and John N. Weinstein
Cancer Res 2003 Mar 1;63(5):1000-11
 |
Read article online |
 |
Supplementary Table 2 is referred to on pages 2, 3, and 7 of the manuscript. It is entitled "A comparison of microarray
results with real time RT-PCR analysis for 18 genes yielded a Pearson correlation coefficient of 0.908" |
 |
Supplementary Figure 2A and B is referred to on pages 5, and 7 of the manuscript. On page 7 it is mistakenly referred to as Figure 6A and B.
It is entitled "Flow cytometric assays for the effect of treatment with wortmannin on cisplatin-induced apoptosis in DU145 and RC0.1 cells.
Studies were done as described in the manuscript for Fig. 2. A, Annexin-V assay. B, APO-BrdUrd assay." |
 |
Figure 4A is the electronic version of the molecular interaction map presented
in the manuscript. |
 |
Abstract:
To study the molecular mechanisms by which drug resistance develops,
we compared DU145 human prostate cancer cells with a subline selected
for resistance to camptothecin. Differences in gene expression level were
assessed by hybridizing the two cell types against each other using quadruplicate
"Oncochip" cDNA microarrays that included 1648 cancerrelated
genes. Expression levels differing by a factor of >1.5 were detected
for 181 of the genes. These differences were judged statistically reliable on
the basis of a stratum-adjusted Kruskal-Wallis test, after taking into
account a dye-dependent variable. The 181 expression-altered genes included
a larger than expected number of the "apoptosis-related" genes
(P = 0.04). To assess whether this observation reflected a generalized
resistance of RCO.1 to apoptosis, we exposed the cells to a range of
stresses (cisplatin, staurosporine, UV, ionizing radiation, and serum starvation)
and found greatly reduced apoptotic responses for RC0.1 (relative
to DU145) using flow cytometric Annexin V and terminal deoxynucleotidyl
transferase-mediated nick end labeling assays. We next examined the
apoptosis-related genes in the context of a molecular interaction map and
found expression differences in the direction "expected" on the basis of the
apoptosis-resistance of RC0.1 for BAD, caspase-6, and genes that signal
via the Akt pathway. Exposure of the cells to wortmannin, an inhibitor of
the Akt effector phosphatidylinositol 3'-kinase, provided functional support
for involvement of the Akt pathway. However, closer examination of
the molecular interaction map revealed a paradox: many of the expression
differences observed for apoptosis-related genes were in the direction
"contrary" to that expected given the resistance of RC0.1. The map
indicated that most of these unexpected expression differences were associated
with genes involved in the nuclear factor κB and transforming
growth factor β pathways. Overall, the patterns that emerged suggested a
two-step model for the selection process that led to resistance in RC0.1
cells. The first hypothesized step would involve a decrease in apoptotic
susceptibility through changes in the apoptosis-control machinery associated
with the Bcl-2 and caspase gene families, and also in antiapoptotic
pathways operating through Akt/PKB. The second step would involve
changes in multifunctional upstream genes (including some genes in the
nuclear factor κB and transforming growth factor β pathways) that can
facilitate apoptosis but that would also tend to contribute to cell proliferation
in the presence of drug. Thus, we propose that a downstream
blockade of apoptosis was "permissive" for the selection of upstream
pathway changes that would otherwise have induced apoptosis. This
model is analogous to one suggested previously for the relationship between
oncogene function and apoptosis in carcinogenesis.
|